» Articles » PMID: 27281113

A Novel Imaging System Distinguishes Neoplastic from Normal Tissue During Resection of Soft Tissue Sarcomas and Mast Cell Tumors in Dogs

Overview
Journal Vet Surg
Date 2016 Jun 10
PMID 27281113
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the ability of a novel imaging system designed for intraoperative detection of residual cancer in tumor beds to distinguish neoplastic from normal tissue in dogs undergoing resection of soft tissue sarcoma (STS) and mast cell tumor (MCT).

Study Design: Non-randomized prospective clinical trial.

Animals: 12 dogs with STS and 7 dogs with MCT.

Methods: A fluorescent imaging agent that is activated by proteases in vivo was administered to the dogs 4-6 or 24-26 hours before tumor resection. During surgery, a handheld imaging device was used to measure fluorescence intensity within the cancerous portion of the resected specimen and determine an intensity threshold for subsequent identification of cancer. Selected areas within the resected specimen and tumor bed were then imaged, and biopsies (n=101) were obtained from areas that did or did not have a fluorescence intensity exceeding the threshold. Results of intraoperative fluorescence and histology were compared.

Results: The imaging system correctly distinguished cancer from normal tissue in 93/101 biopsies (92%). Using histology as the reference, the sensitivity and specificity of the imaging system for identification of cancer in biopsies were 92% and 92%, respectively. There were 10/19 (53%) dogs which exhibited transient facial erythema soon after injection of the imaging agent which responded to but was not consistently prevented by intravenous diphenhydramine.

Conclusion: A fluorescence-based imaging system designed for intraoperative use can distinguish canine soft tissue sarcoma (STS) and mast cell tumor (MCT) tissue from normal tissue with a high degree of accuracy. The system has potential to assist surgeons in assessing the adequacy of tumor resections during surgery, potentially reducing the risk of local tumor recurrence. Although responsive to antihistamines, the risk of hypersensitivity needs to be considered in light of the potential benefits of this imaging system in dogs.

Citing Articles

Machine learning approaches in non-contact autofluorescence spectrum classification.

Raman A, Zachem T, Plumlee S, Park C, Eward W, Codd P PLOS Digit Health. 2024; 3(10):e0000602.

PMID: 39383196 PMC: 11463826. DOI: 10.1371/journal.pdig.0000602.


Progresses in Fluorescence Imaging Guidance for Bone and Soft Tissue Sarcoma Surgery.

Chen Z, Huang H, He S, Wang Y, Cai L, Xie Y Front Oncol. 2022; 12:879697.

PMID: 35860548 PMC: 9289289. DOI: 10.3389/fonc.2022.879697.


The feasibility and utility of optical coherence tomography directed histopathology for surgical margin assessment of canine mast cell tumours.

Dornbusch J, Cocca C, Jennings R, Samuelson J, Vieson M, Huang P Vet Comp Oncol. 2020; 19(4):616-623.

PMID: 32951309 PMC: 9720908. DOI: 10.1111/vco.12654.


Diagnostic accuracy of optical coherence tomography for assessing surgical margins of canine soft tissue sarcomas in observers of different specialties.

Dornbusch J, Selmic L, Huang P, Samuelson J, McLaughlin E, Wavreille V Vet Surg. 2020; 50(1):111-120.

PMID: 32916007 PMC: 9744383. DOI: 10.1111/vsu.13510.


Near-infrared imaging and optical coherence tomography for intraoperative visualization of tumors.

Holt D, Singhal S, Selmic L Vet Surg. 2019; 49(1):33-43.

PMID: 31609011 PMC: 11059208. DOI: 10.1111/vsu.13332.


References
1.
Seguin B, Besancon M, McCallan J, Dewe L, Tenwolde M, Wong E . Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994-2002). J Vet Intern Med. 2006; 20(4):933-40. DOI: 10.1892/0891-6640(2006)20[933:rrcoac]2.0.co;2. View

2.
Kuntz C, Dernell W, Powers B, Devitt C, Straw R, Withrow S . Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986-1996). J Am Vet Med Assoc. 1997; 211(9):1147-51. View

3.
Dennis M, McSporran K, Bacon N, Schulman F, Foster R, Powers B . Prognostic factors for cutaneous and subcutaneous soft tissue sarcomas in dogs. Vet Pathol. 2010; 48(1):73-84. DOI: 10.1177/0300985810388820. View

4.
Lazarides A, Whitley M, Strasfeld D, Cardona D, Ferrer J, Mueller J . A Fluorescence-Guided Laser Ablation System for Removal of Residual Cancer in a Mouse Model of Soft Tissue Sarcoma. Theranostics. 2016; 6(2):155-66. PMC: 4729765. DOI: 10.7150/thno.13536. View

5.
Weisse C, Shofer F, Sorenmo K . Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. J Am Anim Hosp Assoc. 2002; 38(1):71-3. DOI: 10.5326/0380071. View